Evidence map›Paper›PMID 40865594›Full record

ArticleHeart rhythm2026

Myocardial PKG1α dysregulation contributes to ventricular tachycardia pathogenesis in type 2 diabetes and metabolic syndrome.

Xuehong Cao, Yali Zhang, Audrey Tripp, Rachel Steinhauer, Pei-Wen Liu, Mark J Aronovitz, Greg L Martin, Bo Wang, Abdullah Alissa, Mossab Aljuaid and 5 more

Abstract read
In one paragraph

Article in Heart rhythm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Xuehong CaoMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts.
Yali ZhangMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts.
Audrey TrippMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts.
Rachel SteinhauerDepartment of Medicine, Tufts Medical Center, Boston, Massachusetts.
Pei-Wen LiuMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts; Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts.
Mark J AronovitzMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts.
Greg L MartinMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts.
Bo WangMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts.
Abdullah AlissaDivision of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
Mossab AljuaidDivision of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
Justin HoTufts University School of Medicine, Boston, Massachusetts.
Tina PhanTufts University School of Medicine, Boston, Massachusetts.
Christopher MadiasTufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Tufts Medical Center, Boston, Massachusetts; Division of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
Robert M BlantonMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Tufts Medical Center, Boston, Massachusetts; Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts; Division of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts. Electronic address: robert.blanton@tuftsmedicine.org.
Jonas B GalperMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Tufts Medical Center, Boston, Massachusetts; Division of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts. Electronic address: jonas.galper@tuftsmedicine.org.

Funding

Investigating Mixed Lineage Kinase 3 as a blood pressure-independent protein kinase G1 effector in heart failureR01HL162919 · NHLBI · TUFTS MEDICAL CENTER · PI Robert Morris Blanton · 2022 to 2026
$3.9M
A Role of PKG1a and Inhibitors of cGMP Phosphodiesterase in Post MI VT in Mouse Models for Type II Diabetes and Metabolic SyndromeR01HL153433 · NHLBI · TUFTS MEDICAL CENTER · PI GALPER, JONAS BERNARD · 2020 to 2023
$2.7M
NHLBI NIH HHS R01 HL153433NHLBI NIH HHS R01 HL162919
6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (DMII) and metabolic syndrome (MBS) increase ventricular arrhythmia and sudden cardiac death risk.

objectiveThis study aimed to identify mechanisms through which DMII and MBS promote ventricular tachycardia (VT).

methodsWe performed programmed ventricular stimulation on leptin receptor mutant (Db/Db) mice with DMII; high-fat, high-sucrose (HFHS) diet-fed mice with MBS; and cyclic guanosine monophosphate (cGMP)-dependent protein kinase 1 alpha (PKG1α) leucine zipper mutant (LZM) mice, which have neither DMII nor MBS but have disrupted PKG1α signaling.

resultsProgrammed ventricular stimulation induced VT in Db/Db and HFHS diet-fed mice. Both models demonstrated autonomic dysfunction and decreased cGMP owing to decreased cardiac parasympathetic responsiveness. Conversely, cGMP augmentation with soluble guanylate cyclase stimulation (riociguat) or phosphodiesterase 5 inhibition (sildenafil) reduced VT inducibility. PKG1α LZM mice had normal autonomic responsiveness, but excess VT. Left ventricular tissue from HFHS diet-fed and LZM mice demonstrated hyperactivated glycogen synthase kinase-3 beta (GSK3β). GSK3β inhibition with TWS119 abolished inducible VT in all 3 models. Sarcoplasmic reticulum Ca

conclusionIn DMII and MBS, reduced PKG1α signaling drives GSK3β hyperstimulation, calcium dyshomeostasis, and VT. Pharmacologic modulation of these pathways opposes VT pathogenesis.

Indexed as

Cyclic GMP-Dependent Protein Kinase Type IDiabetes Mellitus, Type 2Metabolic SyndromeMyocardiumTachycardia, VentricularAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLMyocytes, CardiacCyclic GMP-Dependent Protein Kinase Type IArrhythmiaAutonomic dysfunctioncGMPDiabetesGSK3βVentricular tachycardia

Identifiers

PMID40865594
PMCPMC12503768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.